NCT05836220 — "Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2" trial site landscape

Public-registry site landscape for NCT05836220, “Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2”, a Secondary Hyperparathyroidism study sponsored by Pathalys Pharma. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05836220 (registry record)
Study title	Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Official title	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-2) With an Open-Label Extension
Sponsor	Pathalys Pharma
Condition(s)	Secondary Hyperparathyroidism; End Stage Kidney Disease
Phase	PHASE3
Listed sites	68
Site countries	United States, Bulgaria, Poland, Portugal, Serbia, Spain

Patient-friendly overview of this study: eichor.com/study/NCT05836220.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05836220 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →